Adderall XR reinstated in Canada

Health Canada reinstated the marketing authorization for ADHD drug Adderall XR from Shire (LSE:SHP; SHPGY) on the recommendation of the New Drug Committee (NDC). In February, Health Canada told SHP to stop selling Adderall XR because of U.S. post-marketing reports of sudden deaths in pediatric patients (see BioCentury Extra, Thursday Feb. 10, 2005). ...